Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Target Price at $60.22

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $60.22.

A number of research firms recently commented on CLDX. UBS Group began coverage on shares of Celldex Therapeutics in a research report on Thursday, February 13th. They set a “buy” rating and a $44.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Finally, HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research note on Thursday, December 19th.

Celldex Therapeutics Stock Down 0.7 %

NASDAQ:CLDX opened at $22.54 on Friday. Celldex Therapeutics has a 52 week low of $20.91 and a 52 week high of $53.18. The firm has a 50 day moving average of $24.63 and a 200 day moving average of $29.62. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of -8.77 and a beta of 1.60.

Institutional Trading of Celldex Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CLDX. Deep Track Capital LP acquired a new stake in shares of Celldex Therapeutics in the fourth quarter worth $38,919,000. Wellington Management Group LLP increased its stake in shares of Celldex Therapeutics by 14.5% in the third quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock worth $314,190,000 after acquiring an additional 1,167,659 shares during the period. Point72 Asset Management L.P. increased its stake in shares of Celldex Therapeutics by 50.8% in the fourth quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company’s stock worth $63,579,000 after acquiring an additional 847,264 shares during the period. Price T Rowe Associates Inc. MD grew its position in Celldex Therapeutics by 23.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company’s stock valued at $89,890,000 after buying an additional 676,771 shares during the period. Finally, Jennison Associates LLC grew its position in Celldex Therapeutics by 32.0% during the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock valued at $45,017,000 after buying an additional 321,325 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.